ORCHPHARMA
Orchid Pharma Limited (ORCHPHARMA) Stock Analysis
Orchid Pharma Limited develops and manufactures generic injectables, oral solids, and APIs for regulated and emerging markets. It has expertise in cephalosporins and sterile formulations. The company supplies global generics players and institutions. It is listed on Indian stock exchanges after restructuring of its pharma operations.
Healthcare › Drug Manufacturers - Specialty & Generic
₹1,006.50
-0.82% 1W | +31.60% 52W
Market Cap
5.1k CR
P/E Ratio
625.2
52W High
₹1143.5
52W Low
₹480
Div. Yield
0%
Beta
0.5
50 DMA
₹1003.5
200 DMA
₹796.6
Profit Margin
3.5%
Inst. Own.
17.3%
🛑 HIT RESISTANCE
🛑 HIT RESISTANCE
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 182.92 | 198.76 | 220.59 | 217.10 | 244.41 | 222.70 | 217.34 | 237.48 | 263.19 | 193.52 | 207.27 | 368.33 | 304.17 |
| Expenses | 160.78 | 175.46 | 185.21 | 188.19 | 211.92 | 192.36 | 190.97 | 209.49 | 268.84 | 194.99 | 205.71 | 338.17 | 290.17 |
| Operating Profit | 22.14 | 23.30 | 35.38 | 28.91 | 32.49 | 30.34 | 26.37 | 27.99 | -5.65 | -1.47 | 1.56 | 30.16 | 14.00 |
| OPM % | 12.10% | 11.72% | 16.04% | 13.32% | 13.29% | 13.62% | 12.13% | 11.79% | -2.15% | -0.76% | 0.75% | 8.19% | 4.60% |
| Other Income | 1.89 | 8.36 | 7.62 | 13.36 | 7.57 | 7.52 | 8.49 | 3.90 | 11.57 | 10.77 | -1.50 | 7.55 | 1.83 |
| Interest | 5.55 | 3.80 | 3.54 | 3.47 | 3.50 | 3.33 | 3.80 | 3.92 | 2.28 | 3.73 | 3.18 | 1.96 | 2.23 |
| Depreciation | 7.71 | 7.84 | 9.27 | 8.42 | 8.44 | 8.63 | 8.61 | 8.87 | 10.53 | 8.90 | 9.03 | 10.90 | 10.95 |
| Profit before tax | 10.77 | 20.02 | 30.19 | 30.38 | 28.12 | 25.90 | 22.45 | 19.10 | -6.89 | -3.33 | -12.15 | 24.85 | 2.65 |
| Tax % | 0.00% | 0.00% | 0.00% | -10.27% | -0.53% | 0.00% | 0.00% | -0.21% | 0.00% | 0.00% | 0.00% | 0.00% | 2.64% |
| Net Profit | 9.40 | 19.80 | 29.43 | 32.96 | 29.35 | 27.24 | 20.78 | 22.29 | -5.69 | -5.72 | -12.61 | 25.84 | 3.22 |
| EPS in Rs | 1.85 | 3.90 | 5.80 | 6.50 | 5.79 | 5.37 | 4.10 | 4.39 | -1.12 | -1.13 | -2.49 | 5.09 | 0.63 |
| Metric | Mar 201518m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,747 | 873 | 797 | 683 | 600 | 484 | 450 | 560 | 666 | 819 | 1,398 | 1,233 | 1,073 |
| Expenses | 1,429 | 703 | 794 | 659 | 612 | 515 | 421 | 505 | 581 | 708 | 1,247 | 1,185 | 1,029 |
| Operating Profit | 317 | 171 | 3 | 24 | -12 | -31 | 29 | 55 | 84 | 111 | 151 | 48 | 44 |
| OPM % | 18% | 20% | 0.4% | 3.6% | -2.0% | -6% | 7% | 10% | 13% | 14% | 11% | 3.9% | 4.1% |
| Other Income | 156 | -28 | -59 | 20 | 218 | 24 | 15 | 67 | 52 | 31 | 26 | 15 | 19 |
| Interest | 537 | 294 | 347 | 310 | 7 | 6 | 52 | 33 | 33 | 17 | 13 | 9 | 11 |
| Depreciation | 325 | 145 | 141 | 133 | 130 | 118 | 109 | 87 | 55 | 33 | 42 | 43 | 40 |
| Profit before tax | -389 | -296 | -544 | -399 | 69 | -131 | -117 | 2 | 48 | 92 | 122 | 10 | 12 |
| Tax % | -49% | -6% | -9% | -12% | 0% | 0% | 0% | 0% | 0% | -3% | -8% | -2% | |
| Net Profit | -197 | -279 | -495 | -353 | 69 | -131 | -117 | -2 | 46 | 92 | 135 | 10 | 11 |
| EPS in Rs | -23.06 | -31.37 | -55.69 | -39.65 | 7.80 | -32.11 | -28.55 | -0.48 | 11.35 | 18.17 | 26.63 | 1.96 | 2.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 23.0% | 22.0% | 4.0% |
| Profit CAGR | 53.0% | 17.0% | 8.0% |
Shareholding Pattern
Promoters69.84%
FIIs1.39%
DIIs19.43%
Public9.34%
Promoters69.84%
FIIs1.56%
DIIs19.04%
Public9.57%
Promoters69.84%
FIIs1.17%
DIIs19.38%
Public9.61%
Promoters69.84%
FIIs0.87%
DIIs20.24%
Public9.04%
Promoters69.84%
FIIs0.80%
DIIs20.75%
Public8.62%
Promoters89.96%
FIIs0.81%
DIIs2.62%
Public6.60%
Promoters69.84%
FIIs1.96%
DIIs17.73%
Public10.47%
Promoters69.84%
FIIs2.69%
DIIs20.10%
Public7.37%
Promoters69.84%
FIIs0.87%
DIIs20.24%
Public9.04%
Promoters69.84%
FIIs0.80%
DIIs20.75%
Public8.62%
ORCHPHARMA
Holdings Analysis
Key strengths & risk signals
71
Overall
57
Fundamental
85
Technical
Risks (1)
Cannot calculate PEG - insufficient growth data.
Strengths (3)
BULLISH TREND! 50-day average (1003.5) is above 200-day average (796.6) - positive signal.
GOOD YEAR! Stock gained 31.6% in the last year.
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 168,151 vs down days: 85,127. Ratio: 1.98x
Fundamental & Technical Analysis
71Overall
57Fundamental
85Technical
Fundamental Breakdown
Growth Quality
17/30
Revenue CAGR: 22.3% (EXCELLENT, 15/15). Profit CAGR: -40.1% (DECLINING, 2/15).
Profit Margin
2/10
LOW MARGIN! 3.5% profit margin - thin profits.
PEG Valuation
1/10
Cannot calculate PEG - insufficient growth data.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
20/20
VERY LESS PUBLIC HOLDING! 5.54% public ownership - strong promoter/institutional control.
Stability Index
4/10
CAREFUL! Company does not have stable profit track. 3 loss-making quarters detected.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (1003.5) is above 200-day average (796.6) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (1006.5) is above both moving averages.
Trend Pattern
10/20
AT RESISTANCE! Stock is at key resistance level.
52W Performance
10/10
GOOD YEAR! Stock gained 31.6% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 10 up days, 20 down days. Avg volume on up days: 168,151 vs down days: 85,127. Ratio: 1.98x
RSI
3/5
NEUTRAL! RSI at 49.4 - balanced momentum.
52W Range
4/5
UPPER HALF! Trading at 79.4% of 52W range - positive territory.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -0.8% (1 week), 5.4% (1 month), 0.4% (3 months).
Beta
5/5
LOW VOLATILITY! Beta of 0.50 - stable stock, less market risk.
ORCHPHARMA
Concall / Investor Presentation
Earnings call transcripts & AI summaries
| Quarter | Concall | Summary |
|---|---|---|
| Q1FY272026-08-24 | Concall PDF | |
| Q4FY262026-06-01 | Concall PDF | |
| Q3FY262026-02-16 | Concall PDF | |
| Q2FY262025-11-17 | Concall PDF |
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORCHPHARMA | ₹1,006.50 | 625.2 | 3.5% | 22.3% | -40.1% | +31.6% | 71 | HIT RESISTANCE | -156.1% | -86.6% | +15.6% | +28.0% |
| GUJTHEM | ₹390.00 | 87.2 | 28.0% | 3.8% | -7.0% | -9.9% | 59 | BREAKDOWN | +22.0% | +1.8% | +22.0% | -0.9% |
| NOVARTIND | ₹2,051.20 | 51.8 | 26.4% | -1.4% | -3.4% | +192.7% | 65 | CONSOLIDATING UP | +16.7% | +27.8% | +18.5% | +14.6% |
| FDC | ₹333.60 | 18.6 | 13.4% | 6.8% | 13.2% | -27.3% | 65 | APPROACHING SUPPORT | +9.1% | +28.1% | +3.0% | +14.2% |
| IOLCP | ₹214.90 | 37.6 | 6.7% | 1.6% | -0.4% | +102.8% | 63 | CONSOLIDATING UP | +90.0% | +21.1% | +37.1% | +22.1% |
| SPARC | ₹196.90 | 4 | 83.0% | -45.3% | – | +48.8% | 60 | APPROACHING RESISTANCE | -59.9% | -101.2% | +315.6% | -97.8% |
| INNOVACAP | ₹1,141.80 | 42.4 | 8.8% | 20.1% | 27.5% | +40.3% | 73 | BREAKDOWN | +42.3% | +15.7% | +34.0% | +5.2% |
| BLISSGVS | ₹676.50 | 53.7 | 13.5% | 7.2% | 22.1% | +345.1% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
Data from TradeAlone · Updated daily
